HideChilds = False
SystemName =
 

ELOCTATE® is approved for: on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding

Delivering innovative therapies

Haemophilia A

ELOCTATE® is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia A (congenital factor VIII deficiency) for:

  • Control and prevention of bleeding episodes.
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
  • Perioperative management (surgical prophylaxis).

ELOCTATE does not contain von Willebrand factor, and therefore is not indicated in patients with von Willebrand's disease.

ELOCTATE is manufactured using a human cell line, using an environment free of animal and human additives.

ELOCTATE is approved for use for the treatment of Haemophilia A in Australia and New Zealand. It is also approved in the United States, Japan, Canada, and other countries.